Skip to Content
Merck
All Photos(2)

Key Documents

MAB4037

Sigma-Aldrich

Anti-PTEN Antibody, CT, clone A2b1

clone A2b1, Chemicon®, from mouse

Synonym(s):

MMAC1, TEP1

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

biological source

mouse

Quality Level

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

A2b1, monoclonal

species reactivity

human, rat, mouse

manufacturer/tradename

Chemicon®

technique(s)

immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG1

suitability

not suitable for immunohistochemistry (Paraffin)

NCBI accession no.

UniProt accession no.

shipped in

wet ice

target post-translational modification

unmodified

Gene Information

Specificity

Specifically recognizes PTEN*, a tumor suppressor protein located on human chromosome 10 (Steck, ′97; Li, ′97; Rhei, ′97) that is often mutated in various types of advanced cancers (Rhei, ′97). The PTEN protein exhibits protein phosphatase activity (Myers, ′97) and can suppress the growth of glioma cells (Furnari, ′97). The antibody recognizes human and mouse PTEN and is specific for the C-terminus. Other species not tested. Reactivity with human fibroblasts, breast epithelial and lung cancer cell lines has been confirmed by western blot, and antibody specificity has been confirmed by peptide blocking studies.

*PTEN is covered under U.S. patents 6,262,242, 6,482,795 and U.S. patent application 10/299,003.

Immunogen

Anti-PTEN was generated by immunization with a 10 amino acid peptide corresponding to amino acids 387-400 near the C-terminus of human PTEN.
Epitope: C-terminus

Application

Anti-PTEN Antibody, C-terminus, clone A2b1 is an antibody against PTEN for use in IC, IH, IP & WB.
Research Category
Signaling
Research Sub Category
PI3K, Akt, & mTOR Signaling
Western blot 1:100 (55 kDa)

Immunocytochemistry

Immunohistochemistry: 1:20 to 1:50 for acetone-fixed, fresh frozen tissue. Not effective for paraffin sections.

Immunoprecipitation 1:10 to 1:20

Protocol for immunohistochemistry of frozen tissue sections on glass slides.

1. Fix sections for 5 minutes with cold acetone.

2. Air dry

3. Wash sections with PBS

4. Add blocking solution (horse serum) for 20 minutes

5. Add diluted PTEN antibody and incubate for 1 hour at room temperature.

6. Wash with PBS

7. Add biotinylated secondary antibody (horse anti-mouse, or equivalent).

8. Incubate for 30 minutes at room temperature.

9. Wash with PBS

10. Detect with ABC (Avidin-Peroxidase-Complex) or equivalent.

11. Wash with PBS

12. Develop with DAB substrate.

13. Hematoxylin dye may be used as a counterstain for visualizing nuclei.Breast tumor tissue gives good staining. Prostate tissue does not stain.Optimal working dilutions must be determined by end user.

Target description

55 kDa

Linkage

Replaces: 04-409

Physical form

Format: Purified
Protein A Purified mouse immunoglobulin in 20 mM sodium phosphate, 250 mM NaCl, pH. 7.6, with 0.1% sodium azide as a preservative.
Protein A purified

Storage and Stability

Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Analysis Note

Control
Breast tumor tissue

Purified active kinase is Catalogue Number 14-488

Other Notes

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Carsten B Schmidt-Weber et al.
European journal of immunology, 32(4), 1196-1204 (2002-04-05)
The phosphatidylinositol phosphatase gene PTEN is a dual specific phosphatase acting on phospho amino acids but also on three phosphorylated inositol phospholipids. Present results demonstrate that PTEN is inducible by costimulatory signals in human CD4(+) T cells. PTEN expression was
Delira Robbins et al.
FEBS letters, 586(23), 4108-4113 (2012-11-06)
Our recent studies suggest a unique role of p53 during the early stage of cancer development. However, how p53 activation is regulated during TPA treatment remains elusive. We used murine skin epidermal JB6 promotion-sensitive (P+) and promotion resistant (P-) cells
Danyu Cui et al.
Molecular medicine reports, 16(5), 7813-7820 (2017-09-26)
A number of short noncoding microRNAs (miRs) have been demonstrated to be highly expressed in many kidney diseases such as renal cancer and lupus nephritis (LN); however, these results have not been extensively investigated. The aim of the present study
Janice B B Lam et al.
PloS one, 4(3), e4968-e4968 (2009-03-26)
Adiponectin is an adipokine possessing beneficial effects on obesity-related medical complications. A negative association of adiponectin levels with breast cancer development has been demonstrated. However, the precise role of adiponectin deficiency in mammary carcinogenesis remains elusive. In the present study
Maria C Pazos et al.
Journal of cellular physiology, 233(8), 5949-5961 (2017-12-22)
Ovarian cancer is the fifth leading cause of cancer-related deaths in women. In the past 20 years, the canonical types of drugs used to treat ovarian cancer have not been replaced and the survival rates have not changed. These facts

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service